106 related articles for article (PubMed ID: 1340065)
1. Interferons in the management of neuroendocrine tumors and their possible mechanism of action.
Oberg K
Yale J Biol Med; 1992; 65(5):519-29; discussion 531-6. PubMed ID: 1340065
[TBL] [Abstract][Full Text] [Related]
2. Endocrine tumors of the gastrointestinal tract: systemic treatment.
Oberg K
Anticancer Drugs; 1994 Oct; 5(5):503-19. PubMed ID: 7858282
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors.
Frank M; Klose KJ; Wied M; Ishaque N; Schade-Brittinger C; Arnold R
Am J Gastroenterol; 1999 May; 94(5):1381-7. PubMed ID: 10235222
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group.
di Bartolomeo M; Bajetta E; Buzzoni R; Mariani L; Carnaghi C; Somma L; Zilembo N; di Leo A
Cancer; 1996 Jan; 77(2):402-8. PubMed ID: 8625251
[TBL] [Abstract][Full Text] [Related]
5. Interferons alone or in combination with chemotherapy or other biologicals in the treatment of neuroendocrine gut and pancreatic tumors.
Oberg K; Eriksson B; Janson ET
Digestion; 1994; 55 Suppl 3():64-9. PubMed ID: 7698540
[TBL] [Abstract][Full Text] [Related]
6. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon.
Janson ET; Oberg K
Acta Oncol; 1993; 32(2):225-9. PubMed ID: 7686765
[TBL] [Abstract][Full Text] [Related]
7. Interferon in the management of neuroendocrine GEP-tumors: a review.
Oberg K
Digestion; 2000; 62 Suppl 1():92-7. PubMed ID: 10940694
[TBL] [Abstract][Full Text] [Related]
8. Combined alpha- and gamma-interferon therapy for malignant midgut carcinoid tumors. A phase I-II trial.
Janson ET; Kauppinen HL; Oberg K
Acta Oncol; 1993; 32(2):231-3. PubMed ID: 8323762
[TBL] [Abstract][Full Text] [Related]
9. Biochemical diagnosis of neuroendocrine GEP tumor.
Oberg K
Yale J Biol Med; 1997; 70(5-6):501-8. PubMed ID: 9825477
[TBL] [Abstract][Full Text] [Related]
10. Phase II clinical trial of parenteral hydroxyurea in combination with fluorouracil, interferon and filgrastim in the treatment of advanced pancreatic, gastric and neuroendocrine tumors.
Kaubisch A; Kaleya R; Haynes H; Rozenblit A; Wadler S
Cancer Chemother Pharmacol; 2004 Apr; 53(4):337-40. PubMed ID: 14704829
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy and biotherapy in neuroendocrine tumors.
Oberg K
Curr Opin Oncol; 1993 Jan; 5(1):110-20. PubMed ID: 8094014
[TBL] [Abstract][Full Text] [Related]
12. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors.
Eriksson BK; Larsson EG; Skogseid BM; Löfberg AM; Lörelius LE; Oberg KE
Cancer; 1998 Dec; 83(11):2293-301. PubMed ID: 9840528
[TBL] [Abstract][Full Text] [Related]
13. Medical treatment of neuroendocrine gut and pancreatic tumors.
Oberg K; Eriksson B
Acta Oncol; 1989; 28(3):425-31. PubMed ID: 2472826
[TBL] [Abstract][Full Text] [Related]
14. Phase II clinical trial of combined natural interferon-beta plus recombinant interferon-gamma treatment of chronic hepatitis B.
Musch E; Högemann B; Gerritzen A; Fischer HP; Wiese M; Kruis W; Malek M; Gugler R; Schmidt G; Huchzermeyer H; Gerlach U; Dengler HJ; Sauerbruch T
Hepatogastroenterology; 1998; 45(24):2282-94. PubMed ID: 9951911
[TBL] [Abstract][Full Text] [Related]
15. The role of interferons in the management of carcinoid tumours.
Oberg K; Eriksson B
Br J Haematol; 1991 Oct; 79 Suppl 1():74-7. PubMed ID: 1834159
[TBL] [Abstract][Full Text] [Related]
16. Gastrointestinal carcinoid tumours. Histogenetic, histochemical, immunohistochemical, clinical and therapeutic aspects.
Wilander E; Lundqvist M; Oberg K
Prog Histochem Cytochem; 1989; 19(2):1-88. PubMed ID: 2662260
[TBL] [Abstract][Full Text] [Related]
17. [Role of interferon in the treatment of renal cancer in adults].
Bergerat JP; Dufour P
Rev Prat; 1992 May; 42(10):1246-52. PubMed ID: 1376937
[TBL] [Abstract][Full Text] [Related]
18. Effects of type I interferons on IGF-mediated autocrine/paracrine growth of human neuroendocrine tumor cells.
Vitale G; van Koetsveld PM; de Herder WW; van der Wansem K; Janssen JA; Colao A; Lombardi G; Lamberts SW; Hofland LJ
Am J Physiol Endocrinol Metab; 2009 Mar; 296(3):E559-66. PubMed ID: 19141687
[TBL] [Abstract][Full Text] [Related]
19. Induction of MxA mRNA in patients with neuroendocrine tumors after interferon treatment. Lack of correlation with antitumor response.
Imam H; Janson ET; Gobl A; Alm G; Oberg K
Anticancer Res; 1995; 15(5B):2191-5. PubMed ID: 8572623
[TBL] [Abstract][Full Text] [Related]
20. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma.
Shojamanesh H; Gibril F; Louie A; Ojeaburu JV; Bashir S; Abou-Saif A; Jensen RT
Cancer; 2002 Jan; 94(2):331-43. PubMed ID: 11900219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
